Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Short Interest Update

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the target of a significant drop in short interest in the month of May. As of May 29th, there was short interest totaling 33,421 shares, a drop of 58.4% from the May 14th total of 80,248 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 57,636 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Trading of Nanobiotix

Several hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC bought a new stake in shares of Nanobiotix in the fourth quarter valued at approximately $390,000. Marshall Wace LLP purchased a new position in Nanobiotix during the fourth quarter valued at approximately $220,000. Optiver Holding B.V. purchased a new position in Nanobiotix during the third quarter valued at approximately $101,000. Finally, Royal Bank of Canada grew its stake in Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after acquiring an additional 2,500 shares in the last quarter. Institutional investors own 38.81% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on NBTX. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. Leerink Partners raised their price objective on shares of Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, June 4th. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th. UBS Group raised their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Finally, TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Nanobiotix has a consensus rating of “Moderate Buy” and a consensus price target of $37.33.

Nanobiotix Stock Up 0.6%

Nanobiotix stock traded up $0.21 during midday trading on Friday, hitting $35.54. 84,271 shares of the stock were exchanged, compared to its average volume of 56,974. Nanobiotix has a 52-week low of $4.18 and a 52-week high of $57.14. The business’s 50-day moving average price is $37.63 and its 200-day moving average price is $29.41.

Nanobiotix (NASDAQ:NBTX) last announced its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The business had revenue of $3.42 million for the quarter. Research analysts predict that Nanobiotix will post 0.19 EPS for the current fiscal year.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.